Two randomized control trials, with a combined 2206 patients, studied the effects of salmon calcitonin (sCT) in patients with symptomatic knee osteoarthritis. Changes in joint space width, pain, function, and safety were evaluated over a 24 month period after treatment began. The results of these trials indicated that salmon calcitonin did not have an effect on joint space width in comparison to placebo and that this treatment was unable to provide reproducible benefits for patient pain and function. The use of salmon calcitonin also resulted in an increased incidence of mild to moderate adverse events.